CN100413539C - 5-ht4受体拮抗剂在制备治疗电生理心房改型的药物中的应用 - Google Patents

5-ht4受体拮抗剂在制备治疗电生理心房改型的药物中的应用 Download PDF

Info

Publication number
CN100413539C
CN100413539C CNB018169511A CN01816951A CN100413539C CN 100413539 C CN100413539 C CN 100413539C CN B018169511 A CNB018169511 A CN B018169511A CN 01816951 A CN01816951 A CN 01816951A CN 100413539 C CN100413539 C CN 100413539C
Authority
CN
China
Prior art keywords
atrium
atrial
administration
mammal
dosage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB018169511A
Other languages
English (en)
Chinese (zh)
Other versions
CN1468112A (zh
Inventor
米雷尔·M·J·邦霍姆
安托万·M·A·布里尔
伯纳德·E·J·古特
贝拉·R·帕特尔
吉利恩·L·谢泼德
尼塔·B·阿明
伯纳德·E·伊尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoire GlaxoSmithKline SAS
Glaxo Group Ltd
Original Assignee
Laboratoire GlaxoSmithKline SAS
Glaxo Group Ltd
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0019410A external-priority patent/GB0019410D0/en
Priority claimed from GB0019523A external-priority patent/GB0019523D0/en
Priority claimed from GB0019524A external-priority patent/GB0019524D0/en
Priority claimed from GB0118919A external-priority patent/GB0118919D0/en
Priority claimed from GB0119022A external-priority patent/GB0119022D0/en
Application filed by Laboratoire GlaxoSmithKline SAS, Glaxo Group Ltd, SmithKline Beecham Corp filed Critical Laboratoire GlaxoSmithKline SAS
Publication of CN1468112A publication Critical patent/CN1468112A/zh
Application granted granted Critical
Publication of CN100413539C publication Critical patent/CN100413539C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CNB018169511A 2000-08-07 2001-08-07 5-ht4受体拮抗剂在制备治疗电生理心房改型的药物中的应用 Expired - Fee Related CN100413539C (zh)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
GB0019410.0 2000-08-07
GB0019410A GB0019410D0 (en) 2000-08-07 2000-08-07 Novel use
GB0019523A GB0019523D0 (en) 2000-08-08 2000-08-08 Novel use
GB0019524A GB0019524D0 (en) 2000-08-08 2000-08-08 Novel use
GB0019524.8 2000-08-08
GB0019523.0 2000-08-08
GB0118919.0 2001-08-02
GB0118919A GB0118919D0 (en) 2001-08-02 2001-08-02 Novel use
GB0119022A GB0119022D0 (en) 2001-08-03 2001-08-03 Novel use
GB0119022.2 2001-08-03

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2008100089999A Division CN101297807A (zh) 2000-08-07 2001-08-07 5-ht4受体拮抗剂在预防或治疗某些心血管疾病中的应用

Publications (2)

Publication Number Publication Date
CN1468112A CN1468112A (zh) 2004-01-14
CN100413539C true CN100413539C (zh) 2008-08-27

Family

ID=27515972

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB018169511A Expired - Fee Related CN100413539C (zh) 2000-08-07 2001-08-07 5-ht4受体拮抗剂在制备治疗电生理心房改型的药物中的应用

Country Status (16)

Country Link
US (3) US20050032866A1 (enExample)
EP (1) EP1311295A2 (enExample)
JP (2) JP2004505930A (enExample)
KR (1) KR20030027010A (enExample)
CN (1) CN100413539C (enExample)
AU (1) AU781276B2 (enExample)
BR (1) BR0113073A (enExample)
CA (1) CA2418904A1 (enExample)
CZ (1) CZ2003366A3 (enExample)
HU (1) HUP0303075A3 (enExample)
IL (1) IL154279A0 (enExample)
MX (1) MXPA03001210A (enExample)
NO (1) NO20030588L (enExample)
NZ (1) NZ524108A (enExample)
PL (1) PL365048A1 (enExample)
WO (1) WO2002011766A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04007857A (es) * 2002-02-14 2004-10-15 Glaxo Group Ltd Composicion farmaceutica que comprende n-((1-butil -4-piperidinil) metil)-3, 4-dihidro-2h -(1, 3)oxazino (3, 2-a)indol -10-carboxamida o sal de la misma, y procedimiento para la misma que comprende granulacion en seco.
GB0211230D0 (en) * 2002-05-16 2002-06-26 Medinnova Sf Treatment of heart failure
EP2366431A1 (en) * 2010-03-19 2011-09-21 Universitätsklinikum Hamburg-Eppendorf Myeloperoxidase as a target in atrial fibrillation
EP3176164B1 (en) 2014-07-30 2019-08-21 Aetas Pharma Co. Ltd. Optical isomer of 1,4-benzothiazepine-1-oxide derivative, and pharmaceutical composition prepared using same

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016045A2 (en) * 1990-04-26 1991-10-31 Smith Kline & French Laboratories Limited Use of 5-ht4 receptor antagonists in the treatment of arrythmias and stroke
EP0501322A1 (en) * 1991-02-25 1992-09-02 Glaxo Group Limited 3-Piperidinylmethylcarboxylate substituted indoles
CN1073173A (zh) * 1991-09-14 1993-06-16 史密丝克莱恩比彻姆有限公司 作为5-羟色胺受体拮抗剂的化合物的制备方法
CN1078471A (zh) * 1992-03-12 1993-11-17 史密丝克莱恩比彻姆有限公司 药品
CN1081677A (zh) * 1992-03-31 1994-02-09 格拉克索公司 取代的苯基氨基甲酸酯和脲
CN1124485A (zh) * 1993-05-26 1996-06-12 森德克斯(美国)股份有限公司 新颖的1-苯基烷酮5-ht4受体配位体
CN1183041A (zh) * 1995-03-16 1998-05-27 伊莱利利公司 吲唑甲酰胺
CN1233250A (zh) * 1996-08-16 1999-10-27 史密丝克莱恩比彻姆有限公司 N－[(1－正丁基－4－哌啶基)甲基]－3,4－二氢－2H－[1,3]噁嗪并[3,2－α]吲哚－10－甲酰胺及其盐的制备方法及在本方法中的中间体的制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2118812C (en) * 1991-09-12 2006-01-17 Francis David King 5-ht4 receptor antagonists
US5998409A (en) * 1992-03-12 1999-12-07 Smithkline Beecham Plc Condensed indole derivatives as 5HT4 -receptor antagonists
US5852014A (en) * 1992-03-12 1998-12-22 Smithkline Beecham P.L.C. Condensed indole derivatives as 5HT4 -receptor antagonists
GB9206989D0 (en) * 1992-03-31 1992-05-13 Glaxo Group Ltd Chemical compounds
SK116394A3 (en) * 1992-03-31 1995-04-12 Glaxo Group Ltd Substituted phenylcarbamates and ureas
NZ535261A (en) * 2000-08-08 2004-12-24 Smithkline Beecham P A tablet comprising the hydrochloride salt of N-(1-nbutyl-4-piperidinyl)methyl]-3,4-[1,3]oxazino[3,2-a] indole-10-carboxamide

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016045A2 (en) * 1990-04-26 1991-10-31 Smith Kline & French Laboratories Limited Use of 5-ht4 receptor antagonists in the treatment of arrythmias and stroke
EP0501322A1 (en) * 1991-02-25 1992-09-02 Glaxo Group Limited 3-Piperidinylmethylcarboxylate substituted indoles
CN1073173A (zh) * 1991-09-14 1993-06-16 史密丝克莱恩比彻姆有限公司 作为5-羟色胺受体拮抗剂的化合物的制备方法
CN1078471A (zh) * 1992-03-12 1993-11-17 史密丝克莱恩比彻姆有限公司 药品
CN1081677A (zh) * 1992-03-31 1994-02-09 格拉克索公司 取代的苯基氨基甲酸酯和脲
CN1124485A (zh) * 1993-05-26 1996-06-12 森德克斯(美国)股份有限公司 新颖的1-苯基烷酮5-ht4受体配位体
CN1183041A (zh) * 1995-03-16 1998-05-27 伊莱利利公司 吲唑甲酰胺
CN1233250A (zh) * 1996-08-16 1999-10-27 史密丝克莱恩比彻姆有限公司 N－[(1－正丁基－4－哌啶基)甲基]－3,4－二氢－2H－[1,3]噁嗪并[3,2－α]吲哚－10－甲酰胺及其盐的制备方法及在本方法中的中间体的制备方法

Also Published As

Publication number Publication date
BR0113073A (pt) 2004-06-22
HUP0303075A3 (en) 2007-03-28
JP2004505930A (ja) 2004-02-26
EP1311295A2 (en) 2003-05-21
MXPA03001210A (es) 2004-08-12
PL365048A1 (en) 2004-12-27
US20050032866A1 (en) 2005-02-10
WO2002011766A2 (en) 2002-02-14
WO2002011766A3 (en) 2002-08-01
IL154279A0 (en) 2003-09-17
NO20030588D0 (no) 2003-02-06
NO20030588L (no) 2003-04-03
US20070015769A1 (en) 2007-01-18
CZ2003366A3 (en) 2004-04-14
US20080125422A1 (en) 2008-05-29
CN1468112A (zh) 2004-01-14
AU781276B2 (en) 2005-05-12
AU7652901A (en) 2002-02-18
HUP0303075A2 (hu) 2003-12-29
NZ524108A (en) 2004-11-26
CA2418904A1 (en) 2002-02-14
KR20030027010A (ko) 2003-04-03
JP2007145869A (ja) 2007-06-14

Similar Documents

Publication Publication Date Title
TW202116307A (zh) 心臟肌小節抑制劑口服調配物
TW200810792A (en) Immediate-release tablet formulations of a thrombin receptor antagonist
EP2716302A1 (en) Prophylactic or therapeutic agent for neuropathic pain associated with guillain-barre syndrome
EP3132803A2 (en) Preventive or therapeutic agent for pain associated with herpes zoster in acute phase
TWI866427B (zh) 雌激素受體降解劑之給藥方案
CN100413539C (zh) 5-ht4受体拮抗剂在制备治疗电生理心房改型的药物中的应用
HUP0003836A2 (hu) Lazofoxifent tartalmazó gyógyszerkészítmények
JP2011517678A (ja) 過活動膀胱の治療のためのウデナフィル、およびアルフゾシンまたはオキシブチニンの組み合わせの使用
JP5925862B2 (ja) セロトニン受容体介在状態を治療する方法及び組成物
US10272075B2 (en) Method and composition for treating an alpha adrenoceptor-mediated condition
CN101297807A (zh) 5-ht4受体拮抗剂在预防或治疗某些心血管疾病中的应用
TWI298022B (en) Pharmaceutical compositions for the prophylaxis or treatment of atrial remodeling or atrial fibrillation
Arneric et al. ABT‐089 [3‐(2 (S)‐pyrrolidinylmethoxy)‐2‐methyl‐pyridine]: An orally effective cholinergic channel modulator with potential once‐a‐day dosing and cardiovascular safety
AU2005203196B9 (en) The use of 5HT4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions
AU2916102A (en) The use of 5HT4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions
JP2009292827A (ja) 炎症治療薬の調製のためのミゾラスチンの使用
AU2916202A (en) The use of 5HT4 receptor antagonists in the prophylaxis or treatment of certain cardiovascular conditions
BRPI0615357A2 (pt) combinação de um agente hipnótico e r (+)-alfa-(2,3-dimetóxi-fenil)-1-[2-(4-fluorofenil)etil]-4-pi peridinometanol e aplicação terapêutica do mesmo

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20051014

Address after: French Marta Leroy

Applicant after: Glaxosmithkline S A S Lab

Co-applicant after: Glaxo Group Ltd.

Address before: French Marta Leroy

Applicant before: Glaxosmithkline S A S Lab

Co-applicant before: Smithkline Beechan Corp.

Co-applicant before: Glaxo Group Ltd.

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20080827

Termination date: 20110807